Compare GCBC & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | AURA |
|---|---|---|
| Founded | 1889 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.5M | 396.8M |
| IPO Year | 1998 | 2021 |
| Metric | GCBC | AURA |
|---|---|---|
| Price | $22.61 | $5.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | 14.5K | ★ 199.2K |
| Earning Date | 01-22-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 1.98 | N/A |
| Revenue | ★ $77,438,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.43 | ★ N/A |
| Revenue Growth | ★ 20.85 | N/A |
| 52 Week Low | $20.00 | $4.35 |
| 52 Week High | $27.62 | $8.27 |
| Indicator | GCBC | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 37.49 |
| Support Level | $21.79 | $4.84 |
| Resistance Level | $22.66 | $5.30 |
| Average True Range (ATR) | 0.59 | 0.33 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 79.02 | 18.00 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.